Fusion proteins containing recombinant cytotoxic RNAses

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S199000, C435S320100, C435S328000, C435S365100, C530S387300, C536S023400, C536S023530

Reexamination Certificate

active

07544487

ABSTRACT:
Recombinant immunotoxins containing a cytotoxic RNAse fused to an antibody or antibody fragment may be produced in mammalian cell culture. Surprisingly, immunotoxins containing a cytotoxic RNAse fused to the N-terminus of one antibody variable domain can be prepared and retain the ability to specifically bind antigen. The immunotoxins may be used in a variety of therapeutic methods for treating diseases or syndromes associated with unwanted or inappropriate cell proliferation or activation.

REFERENCES:
patent: 5650150 (1997-07-01), Gillies
patent: 6045793 (2000-04-01), Rybak et al.
patent: 6472511 (2002-10-01), Leung et al.
patent: 2003/0099629 (2003-05-01), Goldenberg et al.
Stocker et al, Protein Expression and Purification 28: 211-219, Apr. 2003.
Schuurman et al, Molecular Immunology 38: 1-8, 2001.
Rudikoff et al, Proc Natl Acad Sci USA 79: 1979, 1982.
Barrios et al, J Molecular Recognition 17: 332-338, 2004.
Youle, Richard J., et al., “Cytotoxic Ribonucleases and Chimeras in Cancer Therapy” Critical Reviews in Therapeutic Drug Carrier Systems, 10(1):1-28(1993) XP009008208.
Rybak, Susanna M., et al., “Rational Immunotherapy with Ribonuclease Chimeras” Cell Biophysics, vol. 21, 1992, pp. 121-138.
Rybak, Susanna M., et al., “Humanization of Immunotoxins” 6039 Proceedings of the National Academy of Sciences of the USA 89 (1992) Apr. 15, No. 8, Washington, DC, US, pp. 3165-3169.
Newton, Dianne L., et al., “Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma” Blood, Jan. 15, 2001, vol. 97, NUMI XP-002243705.
Notomista, Eugenio, et al., “Effective expression and purification of recombinant onconase, an antitumor protein” FEBS Letters 463 (1999) 211-215 FEBS 23053 Sep. 12, 1999.
Liao, You-Di, et al., “The structural integrity exerted by N-terminal pyroglutamate is crucial for the cytotoxicity of frog ribonuclease from Rana pipiens” Nucleic Acids Research, 2003, vol. 31, No. 18 5247-5255 XP-002392403.
Chang, Chien-Hsing, et al., “Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin” Blood, Dec. 15, 2005, vol. 106, No. 13 XP-002418345.
Youle, Richard J., et al., “Cytotoxic Ribonucleases and Chimeras in Cancer Therapy” Critical Reviews in Therapeutic Drug Carrier Systems, 10(1):1-28(1993).
Rybak, Susanna M., et al., “Rational Immunotherapy with Ribonuclease Chimeras” Cell Biophysics, vol. 21, 1992, pp. 121-138.
Rybak, Susanna M., et al., “Humanization of Immunotoxins” 6039 Proceedings of the National Academy of Sciences of the USA 89 (1992) Apr. 15, No. 8, Washington, DC, US, pp. 3165-3169.
Newton, Dianne L., et al., “Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma” Blood, Jan. 15, 2001, vol. 97, pp. 528-535.
Notomista, Eugenio, et al., “Effective expression and purification of recombinant onconase, an antitumor protein” FEBS Letters vol. 463: 211-251, 1999.
Liao, You-Di, et al., “The structural integrity exerted by N-terminal pyroglutamate is crucial for the cytotoxicity of frog ribonuclease from Rana pipiens” Nucleic Acids Research, 2003, vol. 31, No. 18:5247-5255.
Chang, Chien-Hsing, et al., “Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin” Blood, Dec. 15, 2005, vol. 106, No. 13 pp. 4308-4314.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Fusion proteins containing recombinant cytotoxic RNAses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion proteins containing recombinant cytotoxic RNAses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion proteins containing recombinant cytotoxic RNAses will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4146078

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.